Veronika S. Lysenko
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Loss of SMAD1 in acute myeloid leukemia with KMT2A::AFF1 and KMT2A::MLLT3 fusion genes.
Journal: Frontiers in oncology
Published: August 16, 2024
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis.
Journal: EMBO molecular medicine
Published: May 28, 2024
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.
Journal: Cancer research
Published: April 05, 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Journal: EMBO molecular medicine
Published: March 27, 2023
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Journal: Nature communications
Published: October 22, 2022
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Journal: Nature cancer
Published: July 27, 2022
Calreticulin mutations affect its chaperone function and perturb the glycoproteome.
Journal: Cell reports
Published: July 08, 2021
Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
Journal: Cell chemical biology
Published: November 18, 2020
A patient with a germline GATA2 mutation and primary myelofibrosis.
Journal: Blood advances
Published: September 21, 2020
Last Updated: 09/26/2026